USP704

USP704 is an investigational therapeutic candidate currently in the discovery stage for the treatment of degenerative arthritis (osteoarthritis). Developed by Uscare Pharm, a South Korean biotechnology company specializing in biomaterials and drug delivery systems, USP704 is categorized within the company's "Product Innovation" pipeline. The program likely leverages Uscare Pharm's proprietary material technologies, such as biocompatible polymers or hydrogels, to deliver therapeutic agents or provide structural support to degenerated joints. As of 2024, specific details regarding the drug's molecular target and mechanism of action remain undisclosed in public clinical and scientific literature.